Table 1.
Use of broad-spectrum antibiotics (BSAs) 1 during 26 weeks, pharmacy sales data versus ward stock data.
| Wards BSAs | PharmacyBSA DDDs 2 | WardBSA DDDs | Diff. (%) |
|---|---|---|---|
| Pulmonary diseases | 1 144.8 | 1 194.2 | -4.3 |
| 2nd generation cephalosporins | 445.0 | 432.5 | -2.8 |
| 3rd generation cephalosporins | 328.8 | 360.3 | -9.6 |
| Carbapenems | 180.0 | 171.0 | 5.0 |
| Ciprofloxacin parenteral | 16.0 | 26.4 | -65.0 |
| Ciprofloxacin oral | 175.0 | 204.0 | -16.6 |
| Gastrointestinal/infectious diseases | 877.3 | 898.1 | -2.4 |
| 2nd generation cephalosporins | 205.0 | 231.0 | -12.7 |
| 3rd generation cephalosporins | 161.3 | 152.5 | 5.5 |
| Carbapenems | 103.0 | 96.3 | 6.5 |
| Ciprofloxacin parenteral | 128.0 | 130.0 | -1.6 |
| Ciprofloxacin oral | 280.0 | 288.3 | -3.0 |
| Endocrinology/haematology | 668.3 | 676.1 | -1.2 |
| 2nd generation cephalosporins | 125.0 | 128.0 | -2.4 |
| 3rd generation cephalosporins | 101.3 | 111.3 | -9.9 |
| Carbapenems | 80.0 | 76.0 | 5.0 |
| Ciprofloxacin parenteral | 52.0 | 46.8 | 10.0 |
| Ciprofloxacin oral | 310.0 | 314.0 | -1.3 |
| Urology 1 | 615.3 | 572.8 | 6.9 |
| 2nd generation cephalosporins | 70.0 | 62.5 | 10.5 |
| 3rd generation cephalosporins | 46.3 | 32.8 | 29.2 |
| Carbapenems | 0 | 0 | - |
| Ciprofloxacin parenteral | 124.0 | 131.2 | -5.8 |
| Ciprofloxacin oral | 375.0 | 346.3 | 7.7 |
| Urology 2 | 671.5 | 628.7 | 6.4 |
| 2nd generation cephalosporins | 72.5 | 63.0 | 13.1 |
| 3rd generation cephalosporins | 30.0 | 19.0 | 36.7 |
| Carbapenems | 0 | 0 | - |
| Ciprofloxacin parenteral | 144.0 | 144.4 | -0.3 |
| Ciprofloxacin oral | 425.0 | 402.3 | 5.3 |
| All specialties | 3 977.2 | 3 969.7 | 0.2 |
1BSAs: ciprofloxacin (oral and parenteral), cefuroxime, cefotaxime, ceftazidime, ceftriaxone, meropenem and imipenem/cilastatin
2DDD: defined daily doses